$30.48
-0.77-2.46%
At close: Nov 11, 4:00 PM EST
$30.35
-0.90-2.88%
Pre-Market: 7:44 AM EST
Viridian Therapeutics Inc
VRDNNASDAQ
Viridian Therapeutics rose 7.0% from $28.49 to $30.48, behind the S&P 500's +12.7%. Its worst day was Mar 30 (−32.3%), and its low came Apr 29 at $13.30.
Nov 13, 2025 – Nov 12, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Viridian Therapeutics closed at its highest level of the year, 18.6% above where the year started.
+5.6% · S&P 500 −0.5%
EPS of $-1.08 missed the $-0.96 estimate on $132,000.00 revenue (est. $16.8M).
Story events cover the past 12 months · Times ET
+1.9% · S&P 500 −0.6%
REVEAL-1 met the primary endpoint of Q4W proptosis responder rate (PRR) with a highly statistically significant treatment effect.Elegrobart Q4W and Q8W achieved clinically meaningful 54% and 63% PRR versus 18% placebo at
−32.3%, the year's worst day · S&P 500 −0.3%
EPS of $-0.90 beat the $-1.07 estimate on $141,000.00 revenue (est. $27,750.00).
+33.4%, the year's best day, on 16M shares, the year's heaviest volume · S&P 500 +0.8%
EPS of $-1.05 missed the $-1.02 estimate on $233,000.00 revenue (est. $22,000.00).
+6.8% · S&P 500 −0.2%
EPS of $-0.81 beat the $-1.02 estimate on $25,752.00 revenue (est. $4.9M).
+15.5% · S&P 500 +1.7%
Where it ended: a close of $30.48 on Nov 12, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $-0.75, revenue est. $50.0M).
Nothing in the past 12 months.
All VRDN dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for VRDN and SPY from Benzinga historical bars. Not investment advice.
